DESIGN THERAPEUTICS INC (DSGN) Fundamental Analysis & Valuation

NASDAQ:DSGN • US25056L1035

Current stock price

13.3 USD
-0.3 (-2.21%)
At close:
13.3 USD
0 (0%)
After Hours:

This DSGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. DSGN Profitability Analysis

1.1 Basic Checks

  • DSGN had negative earnings in the past year.
  • DSGN had a negative operating cash flow in the past year.
  • DSGN had negative earnings in each of the past 5 years.
  • DSGN had a negative operating cash flow in each of the past 5 years.
DSGN Yearly Net Income VS EBIT VS OCF VS FCFDSGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -30.85%, DSGN is in the better half of the industry, outperforming 63.37% of the companies in the same industry.
  • The Return On Equity of DSGN (-32.84%) is better than 73.64% of its industry peers.
Industry RankSector Rank
ROA -30.85%
ROE -32.84%
ROIC N/A
ROA(3y)-20.49%
ROA(5y)-18.65%
ROE(3y)-21.36%
ROE(5y)-19.55%
ROIC(3y)N/A
ROIC(5y)N/A
DSGN Yearly ROA, ROE, ROICDSGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • DSGN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DSGN Yearly Profit, Operating, Gross MarginsDSGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. DSGN Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for DSGN has been increased compared to 1 year ago.
  • The number of shares outstanding for DSGN has been increased compared to 5 years ago.
  • DSGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DSGN Yearly Shares OutstandingDSGN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
DSGN Yearly Total Debt VS Total AssetsDSGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • DSGN has an Altman-Z score of 34.04. This indicates that DSGN is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 34.04, DSGN belongs to the best of the industry, outperforming 93.60% of the companies in the same industry.
  • There is no outstanding debt for DSGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 34.04
ROIC/WACCN/A
WACCN/A
DSGN Yearly LT Debt VS Equity VS FCFDSGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 17.14 indicates that DSGN has no problem at all paying its short term obligations.
  • The Current ratio of DSGN (17.14) is better than 93.60% of its industry peers.
  • DSGN has a Quick Ratio of 17.14. This indicates that DSGN is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 17.14, DSGN belongs to the top of the industry, outperforming 93.60% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.14
Quick Ratio 17.14
DSGN Yearly Current Assets VS Current LiabilitesDSGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. DSGN Growth Analysis

3.1 Past

  • The earnings per share for DSGN have decreased strongly by -38.64% in the last year.
EPS 1Y (TTM)-38.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, DSGN will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.51% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-17.61%
EPS Next 2Y-17.63%
EPS Next 3Y-18.94%
EPS Next 5Y8.51%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DSGN Yearly Revenue VS EstimatesDSGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
DSGN Yearly EPS VS EstimatesDSGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2 -2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. DSGN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DSGN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DSGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DSGN Price Earnings VS Forward Price EarningsDSGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DSGN Per share dataDSGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • A cheap valuation may be justified as DSGN's earnings are expected to decrease with -18.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.63%
EPS Next 3Y-18.94%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DSGN Dividend Analysis

5.1 Amount

  • No dividends for DSGN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DSGN Fundamentals: All Metrics, Ratios and Statistics

DESIGN THERAPEUTICS INC

NASDAQ:DSGN (5/1/2026, 8:22:21 PM)

After market: 13.3 0 (0%)

13.3

-0.3 (-2.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-09
Earnings (Next)05-11
Inst Owners61.48%
Inst Owner Change0.05%
Ins Owners1.97%
Ins Owner Change0%
Market Cap820.21M
Revenue(TTM)N/A
Net Income(TTM)-69.79M
Analysts86.67
Price Target14.96 (12.48%)
Short Float %5.52%
Short Ratio7.58
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.78%
Min EPS beat(2)14.33%
Max EPS beat(2)25.22%
EPS beat(4)2
Avg EPS beat(4)7.5%
Min EPS beat(4)-8.54%
Max EPS beat(4)25.22%
EPS beat(8)6
Avg EPS beat(8)10.8%
EPS beat(12)10
Avg EPS beat(12)14.04%
EPS beat(16)11
Avg EPS beat(16)9.89%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.19%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.86
P/tB 3.86
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)-1.43
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0
BVpS3.45
TBVpS3.45
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -30.85%
ROE -32.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.49%
ROA(5y)-18.65%
ROE(3y)-21.36%
ROE(5y)-19.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.05%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.14
Quick Ratio 17.14
Altman-Z 34.04
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)109.7%
Cap/Depr(5y)462.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
EPS Next Y-17.61%
EPS Next 2Y-17.63%
EPS Next 3Y-18.94%
EPS Next 5Y8.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-68.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.39%
OCF growth 3YN/A
OCF growth 5YN/A

DESIGN THERAPEUTICS INC / DSGN Fundamental Analysis FAQ

What is the ChartMill fundamental rating of DESIGN THERAPEUTICS INC (DSGN) stock?

ChartMill assigns a fundamental rating of 3 / 10 to DSGN.


Can you provide the valuation status for DESIGN THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to DESIGN THERAPEUTICS INC (DSGN). This can be considered as Overvalued.


Can you provide the profitability details for DESIGN THERAPEUTICS INC?

DESIGN THERAPEUTICS INC (DSGN) has a profitability rating of 1 / 10.


What is the earnings growth outlook for DESIGN THERAPEUTICS INC?

The Earnings per Share (EPS) of DESIGN THERAPEUTICS INC (DSGN) is expected to decline by -17.61% in the next year.